A collection of clinical and translational investigations highlights the shared molecular mechanisms, diagnostic indices, and ...

The recent FDA approvals of pharmacologic therapies for metabolic dysfunction-associated steatohepatitis were “breakthrough moments in history” for a disease whose management had mostly relied on ...

A study of 587 patients demonstrates that circulating oxidized low-density lipoprotein associates with inflammatory activity ...

Zydus Therapeutics  Inc. ("Zydus Therapeutics"), a wholly owned subsidiary of Zydus Lifesciences Limited, a global innovation ...

Semaglutide shows promise in improving liver health and metabolic outcomes in MASH, enhancing steatohepatitis resolution and cardiometabolic measures. A large meta-analysis, published in Diabetology & ...

Merck announced the presentation of positive results from the company?s Phase 2b clinical trial that evaluated the safety and ...

Nonalcoholic fatty liver disease (NAFLD), now reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), and its more severe form, nonalcoholic steatohepatitis (NASH), renamed ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and hepatocellular carcinoma. While fibroblast growth factor 21 (FGF21) analogs have shown ...

Cytokine release from inflammatory cells, endotoxin, lipid peroxidation, and generation of reactive oxygen species are among the factors currently thought to be important in the pathogenesis of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company’s Phase 2b clinical trial that evaluated the safety and ...